<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743482</url>
  </required_header>
  <id_info>
    <org_study_id>INT123/12</org_study_id>
    <nct_id>NCT01743482</nct_id>
  </id_info>
  <brief_title>Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors</brief_title>
  <acronym>Pazotest-01</acronym>
  <official_title>Phase II Study of Single-agent Pazopanib (VotrientÂ®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, single center, phase 2 study with the use of the&#xD;
      antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell&#xD;
      tumors who are not cured following first or subsequent chemotherapy lines for metastatic&#xD;
      disease, followed by eventual surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2013</start_date>
  <completion_date type="Actual">July 27, 2016</completion_date>
  <primary_completion_date type="Actual">July 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3-months</time_frame>
    <description>To evaluate the proportion of patients who are progression-free after 3 months of pazopanib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of pazopanib according to the Common Terminology Criteria for Adverse Events version 4.03</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 months</time_frame>
    <description>A response rate will be considered as the sum of complete (CR) and partial responses (PR) according to the response evaluation criteria in solid tumors (RECIST), version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>OS time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive. The Kaplan-Meier method will be used to estimate the OS curve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Germ Cell Tumors</condition>
  <condition>Measurable Disease</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>Pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male gender.&#xD;
&#xD;
          -  Confirmation of GCT histology based on pathologic review at Fondazione INT Milan.&#xD;
&#xD;
          -  Unequivocal progression of measurable disease.&#xD;
&#xD;
          -  A minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic&#xD;
             disease.&#xD;
&#xD;
          -  First-line therapy should consist of at least 3 cycles of cisplatin-based&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Prior single, tandem or triple high-dose chemotherapy course given as front-line or&#xD;
             salvage therapy is allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet any of the above inclusion criteria.&#xD;
&#xD;
          -  Concurrent treatment with other cytotoxic drugs or targeted therapies.&#xD;
&#xD;
          -  Prior radiation therapy within 14 days of trial start.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Mi</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Andrea Necchi</investigator_full_name>
    <investigator_title>Faculty, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Testicular Cancer</keyword>
  <keyword>Germ Cell Tumors</keyword>
  <keyword>Salvage Therapy</keyword>
  <keyword>Pazopanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

